Navigation Links
ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
Date:6/10/2008

vide very high levels of purification. This is achieved by use of small chemical affinity ligands designed to bind a target biomolecule specifically and reversibly. In view of their use for the production of therapeutics, ProMetic's affinity products are manufactured according to a strict quality system based on good manufacturing practice at PBL's ISO 9001:2000 certified manufacturing facility on the Isle of Man, which completed a (pnds stlg)1.5 million expansion in 2005. PBL also operates an R&D laboratory located on the Cambridge Science Park, UK.

About Octapharma AG

Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality human proteins. The Company has grown to 2,500 employees in 27 countries since its founding in 1983. Octapharma owns five modern, state-of-the-art production facilities in Austria, France, Sweden, Mexico and Germany. Sales turnover in 2007 exceeded Euro 752 million. Octapharma continues to grow and invest heavily in the future. Profits are mainly channeled into R&D and further improvements and expansion of Production. In the highly demanding market of life-saving plasma products, Company success is only possible through reliable product quality and a proven safety record.

About Octaplas(R)

Octaplas(R) is a pharmaceutical quality human coagulation active plasma for transfusion. Besides being solvent/detergent virus inactivated, the product is standardized, which promotes a better planning and monitoring of treatment. Furthermore, the removal of all residual blood cells and neutralization of both allergens and antibodies against leukocytes render this medicinal product virtually free from causing allergic reactions and the risk for transfusion-related acute lung injuries ("TRALI"), being the most common cause of death in transfusion medicine, has been abolished. Octaplas(R) increases through these multiple fav
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Prometic provides information for its Annual and Special Meeting of Shareholders
2. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
3. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
4. Prometic to present at the American Chemical Society
5. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
6. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
7. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
8. ProMetic provides business update - Over $35 million worth of business secured in January
9. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
10. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
11. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , Nov. 27, 2014 ... the "Global Palmitic Acid Industry Report 2014" ... The Global Palmitic Acid Industry ... the current state of the global palmitic acid industry. ... the industry including definitions, classifications, applications and industry chain ...
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... The North America Thermal Protective Clothing Market ... analysis of the growth trends and revenue forecasts. ... by 2018, growing at a CAGR of 7.1% ... TOC of the North America Thermal Protective Clothing ... in-depth analysis and industry segmentation supported by various ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... ended March 31, 2009. Arena reported a net loss allocable ... $50.6 million, or $0.68 per share, compared to a net ... 2008 of $55.0 million, or $0.75 per share. "Receiving the ...
... Inc. (Nasdaq: IDIX ) announced today that Idenix ... Bank 2009 Health Care Conference on Monday, May 18, 2009 ... and archived webcast of the company presentation can be accessed ... www.idenix.com . Please log in approximately ...
... 18, 2009 SAN DIEGO, May 11 Neurocrine Biosciences, ... Kevin Gorman, President and Chief Executive Officer of Neurocrine ... Annual Health Care Conference in Boston. The live presentation ... Eastern Time (ET)/2:05 p.m. Pacific Time (PT). The ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference 2
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Hospital (MGH) Cancer Center have identified a subgroup of ... drug cisplatin, rarely used in the treatment of breast ... of this sensitivity, which may help identify patients most ... will be tested in a clinical trial anticipated to ...
... delivered into the tumors of stage 4 lung cancer ... phase I clinical trial at The University of Texas ... found to be active in the metastatic non-small cell ... first-in-human study and we've seen an exciting proof of ...
... cut back on the amount of salt in their diet could ... to a report on bmj.com today. , Researchers in ... risk of death from cardiovascular disease by up to a fifth. ... diseases linked to the heart or arteries, for example a stroke ...
Cached Biology News:Molecular signature may identify cisplatin-sensitive breast tumors 2Molecular signature may identify cisplatin-sensitive breast tumors 3Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer 2Eating less salt could prevent cardiovascular disease 2
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
Biology Products: